Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-01-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于公司高级管理人员职务调整及聘任财务总监的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in senior management positions, specifically the resignation of the current CFO and the appointment of a new CFO. It includes details about the new appointee's qualifications and compliance with relevant laws and regulations. There is no financial data, report, or presentation content. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's senior management.
2022-01-17 Chinese
独立董事对公司第九届董事会第三次会议相关事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors regarding the appointment of a new senior management member (financial director) at the company. It references compliance with listing rules and company bylaws, and it is focused on management changes rather than financial results or reports. The document length is short (512 characters), and it is clearly about management appointment approval. Therefore, it fits best under Board/Management Information (MANG).
2022-01-17 Chinese
第九届董事会第三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the third meeting of the ninth board of directors of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and specifically mentions the appointment of senior management including a financial director. The document references compliance with laws and company bylaws and includes a note about related independent director opinions. The content focuses on board/management changes rather than financial results, audit, or other report types. The document length is short (670 characters) and it is not an announcement of a report publication but a direct announcement of board decisions. Therefore, it fits the category of Board/Management Information (MANG).
2022-01-17 Chinese
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining a drug registration certificate from the national drug regulatory authority. It details the drug name, specifications, registration details, and the potential impact on the company. The document is short (1191 characters) and is an announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category, as it informs investors about a material event related to the company's operations but is not a financial or governance filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-01-17 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of the company Northeast Pharmaceutical Group Co., Ltd. It discusses stock price movements, clarifies no undisclosed material information, mentions insider share purchases, and provides risk warnings. It does not contain financial statements or detailed financial performance data. The document length is 2244 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits the category of a regulatory announcement about stock trading and company disclosures, which aligns with Regulatory Filings (RNS).
2022-01-04 Chinese
监事会关于公司核销资产的审核意见
Audit Report / Information Classification · 90% confidence The document is a supervisory board's audit opinion on the company's asset write-off, confirming compliance with accounting standards and internal management rules. It is a formal statement of approval rather than a full audit report or financial statement. The document is short (276 characters) and does not contain detailed financial data or comprehensive audit results. It is not an Annual Report, Audit Report, or Interim Report. It is also not an announcement of voting results or management changes. The content fits best under Audit Report / Information (AR) as it relates to audit opinions on asset write-offs by the supervisory board. FY 2021
2021-12-31 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.